Immune Checkpoint Inhibitors: all 7,814 studies that test it
Page 11 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.
- Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothelial CancerRecruitingNCT06892860Phase 2
- A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung CancerRecruitingNCT06892548Phase 1/2
- Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung CancerRecruitingNCT06890598Phase 3
- Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast CancerRecruitingNCT06889688Phase 3
- SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCCRecruitingNCT06889649Phase 2
- SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)RecruitingNCT06889493Phase 1
- Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.Not yet recruitingNCT06888648Phase 1/2
- Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric CancerNot yet recruitingNCT06888037Phase 2
- Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain MetastasesRecruitingNCT06887088Phase 2
- A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal CancerRecruitingNCT06885385Phase 2
- An Exploratory Clinical Study on Neoadjuvant Treatment of Hepatocellular Carcinoma with QL1706 Combined with LenvatinibNot yet recruitingNCT06884982Phase 2
- An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients with Non-Small Cell Lung CancerNot yet recruitingNCT06883552Phase 2
- Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory LymphomaRecruitingNCT06883526Phase 1/2
- Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular SubtypingNot yet recruitingNCT06881017Phase 2
- First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant TumorsRecruitingNCT06877650Phase 1/2
- Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural MesotheliomaRecruitingNCT06875076Phase 2
- Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for Total Neoadjuvant Therapy of Microsatellite Stable (MSS) Locally Advanced Low Rectal CancerNot yet recruitingNCT06872606Phase 2
- Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric CancerNot yet recruitingNCT06871527Phase 1/2
- Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell LymphomaEnrolling by invitationNCT06871007Phase 1/2
- Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19.RecruitingNCT06869473Phase 2
- A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal CancerRecruitingNCT06869226Phase 2
- A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous CarcinomaRecruitingNCT06869213Phase 2
- TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell CancerRecruitingNCT06868433Phase 1
- A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung CancerRecruitingNCT06868277Phase 3
- Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON TrialRecruitingNCT06866262Phase 1/2
- Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma SubtypeRecruitingNCT06863402Phase 2
- Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCCNot yet recruitingNCT06861894Phase 2
- Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast CancerRecruitingNCT06860815Phase 2
- Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast CancerRecruitingNCT06860529Phase 2
- Cryoablation Combined With Lenvatinib Plus Tislelizumab Compared With FOLFOX in Patients With Advanced Intrahepatic Cholangiocarcinoma (CASTLE-ZS-01)RecruitingNCT06860477Phase 2
- Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)RecruitingNCT06859684Phase 2
- A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Rheumatoid ArthritisRecruitingNCT06857227Phase 1
- A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Systemic Lupus ErythematosusRecruitingNCT06857214Phase 1
- - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver MetastasesRecruitingNCT06856837Phase 2
- A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinomaNot yet recruitingNCT06855225Phase 2
- Second-line Immunotherapy for ES-SCLCRecruitingNCT06853678Not applicable
- QL1706 in Combination With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemotherapy for Locally Advanced, Resectable Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06852456Phase 2
- GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.RecruitingNCT06851247Phase 2
- SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With OligometastasesRecruitingNCT06850103Phase 2
- IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)RecruitingNCT06849986Phase 2
- HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast CancerNot yet recruitingNCT06849492Phase 2
- Ivonescimab Plus Chemotherapy in Patients With Initially Unresectable Colorectal Cancer Liver MetastasesRecruitingNCT06848842Phase 2
- LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver MetastasisRecruitingNCT06848465Phase 1
- A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma TreatmentEnrolling by invitationNCT06848088Phase 2
- Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal CancerRecruitingNCT06846268Phase 2
- NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer PatientsRecruitingNCT06845319Phase 2
- Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND)RecruitingNCT06844422Phase 1/2
- A Phase II Study of Toripalimab Combined With Sequential Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell CarcinomaRecruitingNCT06843889Phase 2
- The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-RadiationRecruitingNCT06843551Phase 2
- A Study of Botensilimab and Balstilimab for Rectal AdenocarcinomaRecruitingNCT06843434Phase 2
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)RecruitingNCT06841354Phase 3
- Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal CancerRecruitingNCT06841159Phase 2
- Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line TreatmentRecruitingNCT06841055Phase 2
- Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and ChemotherapyRecruitingNCT06840834Phase 2
- MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal CancerRecruitingNCT06840665Phase 2
- Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic CarcinomaRecruitingNCT06838910Phase 2
- A Multicenter, Open Phase IIb Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Colorectal CancerNot yet recruitingNCT06838546Phase 2
- Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLCRecruitingNCT06838208Phase 2
- Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLCNot yet recruitingNCT06837948Phase 2
- SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.Not yet recruitingNCT06835179Phase 2
- Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI TreatmentRecruitingNCT06830694Phase 2
- Phase II Study of Neoadjuvant Dostarlimab in Patients With Untreated T3-4N0-2 or Stage III pMMR/MSS Resectable Colon CancerRecruitingNCT06830239Phase 2
- A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast CancerRecruitingNCT06827236Phase 1/2
- Clinical Studies for the Treatment of Advanced Solid TumorsRecruitingNCT06825494Phase 1/2
- ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a MuRecruitingNCT06824363Early Phase 1
- Towards Cure Via Only Ultra-short ICB in CSCCRecruitingNCT06823479Phase 2
- 9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial CarcinomaRecruitingNCT06823427Phase 2
- QL1706 As Second-line Treatment in Patients with Advanced Hepatocellular CarcinomaNot yet recruitingNCT06822985Phase 1
- A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)RecruitingNCT06822543Phase 2
- SHR-A2102 Combined With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast CancerNot yet recruitingNCT06819319Phase 2
- Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and RelatlimabRecruitingNCT06816927Phase 2
- Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal CancerNot yet recruitingNCT06814158Phase 2
- Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT06814067Phase 2
- PD-1 Inhibitors Maintenance for cHL Post-autoHCTRecruitingNCT06812858Phase 2
- HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of RecurrenceRecruitingNCT06812039Phase 2
- Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder CancerRecruitingNCT06809140Phase 2
- Adebrelimab Combined With Nab-paclitaxel, Oxaliplatin and Tegafur (AOS) for Perioperative Treatment of Locally Advanced Resectable GC/GEJRecruitingNCT06808971Phase 2
- A Study of Valemetostat in Combination With Atezolizumab in People With Lung CancerRecruitingNCT06807632Phase 1
- Pembrolizumab Concurrent With and Following Carbon-ion Radiotherapy for Locally Advanced Cervical AdenocarcinomaNot yet recruitingNCT06805864Phase 2
- A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland CancersRecruitingNCT06805617Phase 2
- EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal CarcinomaRecruitingNCT06802835Phase 1/2
- Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal CancerRecruitingNCT06802666Phase 2
- A Study Evaluating Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung CancerRecruitingNCT06800339Phase 1
- A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)RecruitingNCT06796907Phase 1/2
- SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III MelanomaRecruitingNCT06794775Phase 3
- Pembrolizumab and Pemetrexed for Progressive ChordomaRecruitingNCT06794645Phase 2
- Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable MetastasisRecruitingNCT06794229Phase 2
- SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver MetastasesRecruitingNCT06794086Phase 3
- Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingNCT06793917Phase 3
- A Phase II Study to Evaluate the Efficacy and Safety of Salvage Preoperative PD-1 Inhibitor Combined with Chemotherapy Neoadjuvant Therapy in Recurrent and Metastatic LPSCC/HPSCCNot yet recruitingNCT06793761Phase 2
- Nanocrystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC CachexiaNot yet recruitingNCT06793228Phase 2
- PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric CancerRecruitingNCT06792162Phase 2
- Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian CancerRecruitingNCT06791460Phase 2/3
- Low-dose Radiotherapy Combined With Chemotherapy and AK112 as Second-line Treatment in Patients With Advanced G/GEJ CancerRecruitingNCT06791148Phase 2
- Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric CancerRecruitingNCT06791083Phase 2
- Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic AdenocarcinomaRecruitingNCT06790602Phase 2
- Neoadjuvant CAPOX Plus Ivonescimab Versus CAPOX for Locally Advanced Colon CancerNot yet recruitingNCT06790212Phase 2
- Ligufalimab and Cadonilimab in Advanced Liver CancersRecruitingNCT06789848Phase 2
- a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy.Not yet recruitingNCT06789796Phase 3
- The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)RecruitingNCT06789757Phase 2